focus -WSS

focus

author：fashion 2025-10-01 02:28:34 - browse：481

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement. It came up most recently in the trials of two police officers accused of causing the death of Elijah McClain, a Colorado man; both officers were acquitted this week.

But excited delirium is not an evidence-based medical diagnosis. The American College of Emergency Physicians recently withdrew a 2009 white paper endorsing the concept, and California has banned it as a cause of death. Other states may follow suit.

On this week’s episode, we are joined by Utsha G. Khatri, an assistant professor of emergency medicine and population health and policy at the Icahn School of Medicine at Mount Sinai, and emergency physician Brooks Walsh, who was involved with the campaign to get ACEP to withdraw the 2009 white paper. Khatri and Walsh speak about why the “excited delirium” label is both unnecessary and dangerous.

“We recognize that some patients are confused. They’re not thinking clearly they might have risk for becoming violent either toward themselves or towards other staff,” Khatri said. “It is our job not just to keep them and everyone else safe, but also to most importantly find out what is causing them to act in this way.”

You can read Khatri’s First Opinion essay on the end of “excited delirium” here.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Hollywood unions extend contract negotiations for actors
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

hotspot

leisure time

WSS

Male and female sex labels in research insufficient, scientists say

A new approach to psychiatric drug development

First U.S. drug developed to treat liver disease MASH is approved

Readout Newsletter: CAR

Stem cell biologist probes earliest stages of human development

FDA advisers back CAR

Wikipedia

focus

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Ebola: Gilead Sciences antiviral shows promise as new treatment

Hollywood unions extend contract negotiations for actors

Medicare coverage of Wegovy, once blocked, now looks possible

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: BridgeBio, Akero, and human embryo models

At least 13 dead in Texas as scorching temps continue

Why scientists need input from humanists on sensitive research

State Dept. review finds Biden bears some blame for Afghanistan failures

WuXi out of biotech trade group, U.S. and China relations to blame

leisure time

First U.S. drug developed to treat liver disease MASH is approved

How to save health care price transparency rules

State of the Union pitch: Bigger Medicare drug price negotiations

How many hemophilia patients actually want gene therapy?

The untold story of TV’s first prescription drug ad

UCLA team creates talking throat patch for voice disorders

hotspot

leisure time

focus

hotspot